FEP 2.04.76 Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

Effective Date: April 1, 2019

Related Policies:
5.21.06 Herceptin (Trastuzumab)

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

Description
Novel assays that quantitatively measure total human epidermal growth factor receptor 2 (HER2) protein expression and homodimers have been developed to improve the accuracy and consistency of HER2 testing.

OBJECTIVE
The objective of this evidence review is to determine whether assessment of human epidermal growth factor receptor 2 (HER2) status using quantitative total HER2 protein expression and HER2 homodimer measurement improves the net health outcome in patients with breast cancer.

POLICY STATEMENT
The assessment of human epidermal growth factor receptor 2 (HER2) status by quantitative total HER2 protein expression and HER2 homodimer measurement is considered investigational.

POLICY GUIDELINES

GENETIC COUNSELING
Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual’s family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION
Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient’s existing medical condition. Benefits are not provided for genetic
FEP 2.04.76 Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. HERmark® Breast Cancer Assay (Monogram Biosciences) is available under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

RATIONALE

Summary of Evidence

For individuals who have breast cancer and are undergoing assessment of HER2 status who receive quantitative total HER2 protein expression and HER2 homodimer measurement, the evidence includes validation studies and retrospective analysis of the association between levels and survival outcomes. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and test validity. Retrospective analysis using HERmark have shown that the assay may predict a worse response to trastuzumab in certain populations. However, findings have been inconsistent, and no clear association with clinical outcomes has been shown. Additionally, cut points for defining patient groups varied across studies. Clinical utility of the HERmark assay has not been demonstrated. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

National Comprehensive Cancer Network guidelines on the treatment of breast cancer (v.3.2018) do not address the use of HERmark.21

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

Palmetto GBA determines coverage and reimbursement for laboratories that perform molecular diagnostic testing and submit claims to Medicare in Medicare Jurisdiction E (California, Nevada, Hawaii). Palmetto GBA’s decisions apply for all molecular diagnostic tests for Medicare.

Palmetto GBA has assessed HERmark and determined that the test meets criteria for analytic and clinical validity and clinical utility as a reasonable and necessary Medicare benefit.22 Effective December 9, 2011, Palmetto GBA will reimburse HERmark services for patients with breast cancer.
REFERENCES


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
FEP 2.04.76 Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers


POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2012</td>
<td>New Policy</td>
<td></td>
</tr>
<tr>
<td>December 2012</td>
<td>Update Policy</td>
<td>Policy and references updated with literature search, no change in policy statement.</td>
</tr>
<tr>
<td>December 2013</td>
<td>Update Policy</td>
<td>Policy updated with a literature search with references added. No change in policy statement. Reference 14 updated.</td>
</tr>
<tr>
<td>December 2014</td>
<td>Update Policy</td>
<td>Policy updated with literature review. References 11, 14–16, and 18 added; references 3 and 17 updated. No change to policy statement.</td>
</tr>
<tr>
<td>March 2018</td>
<td>Update Policy</td>
<td>Policy updated with literature review through October 17, 2017; references 1-3, 5, 7, and 10 added; reference 22 updated. Policy statement unchanged.</td>
</tr>
<tr>
<td>March 2019</td>
<td>Update Policy</td>
<td>Policy updated with literature review through October 30, 2018; references 17-20 added. Policy statement unchanged.</td>
</tr>
</tbody>
</table>